Pharmaceutical

IMA-203CD8 by Immatics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).

Jun 20, 2024 - 04:00
IMA-203CD8 by Immatics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).
Read the original article

Tags:

Previous Article

IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval

Next Article

SGNB-7H4V by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA efforts to oversee foreign drug manufacturing remain inadequate to ensure safety, analysis finds

STAT+: FDA efforts to oversee foreign drug manufacturin...

Dec 5, 2023

BioNTech shelves oral mRNA vaccine plans with Matinas

BioNTech shelves oral mRNA vaccine plans with Matinas

May 12, 2023

Dren Bio and Novartis link on bispecific antibodies for cancer

Dren Bio and Novartis link on bispecific antibodies for...

Jul 26, 2024